Search results

11 results for obinutuzumab

Sorted by Relevance . Sort by Date

  1. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

  2. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for treating untreated chronic lymphocytic leukaemia

  3. Non-Hodgkin's lymphoma

    Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

  4. Blood and bone marrow cancers

    Everything NICE has said on blood and bone marrow cancers including leukaemia in an interactive flowchart

  5. Technology appraisal block scoping reports

    This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.